The FDA should back off of 23andMe and allow the firm to continue selling its consumer genomics service because it is unlikely to lead to unnecessary diagnostic tests and medical procedures, argues Forbes writer Frida Polli.
Registering provides access to this and other free content.
Already have an account?Login Now.
In Science this week: convergent evolution in bird hemoglobin, and more.
The Wall Street Journal speaks with patients affected by questionable test results from Theranos.
Researchers link variants in TACR3 to hot flashes during menopause, Live Science reports.
Kuwait says it will alter its law requiring citizens and visitors to provide DNA samples, New Scientist reports.